MGL-3196 (resmetirom)

resmetirom · Madrigal Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MGL-3196 (resmetirom), covering 2025-12-23 to 2025-12-23. Get the full timeline:

Most recent: Clinical Trial Update: Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) [Phase 2]